SAFE, PRIVATE & SECURE
Your iOPharma™ account is password protected and safe from prying eyes. All iOPharma™ plans include SSL security - the same as online banks. Your data is secure.
SUPPORT FOR MULTIPLE LANGUAGES
iOPharma™ will be translated into Chinese, Spanish, French, German and Portuguese. More languages will be added to this list as time goes on. To find out more about the translations, please contact us at info@io-pharma.com.
FREE REGISTRATION
Whether you’re a buyer or a supplier the iOPharma™ platform will benefit your organisation.
REGISTER NOW
Doctors on social media slam NICE diabetes guidance
Doctors are seemingly outraged by new draft guidelines on the treatment of diabetes published by...
Read morePharma is boosting pipelines to avoid patent cliff
Pharmaceutical companies have improved their pipelines of new drugs over the last 18 months...
Read moreUruguay Marijuana Licenses Lure Bidders From Canada to Germany
(Bloomberg) -- Canadian medical-marijuana producer Tilray and the founder of a German cannabis...
Read moreAstraZeneca plc Lowered to “Underweight” at Barclays
Barclays lowered shares of AstraZeneca plc (LON:AZN) to an underweight rating in a research report...
Read moreInstitute of Medicine Maps Out Clinical Trial Data Sharing Program
Investigators and sponsors of clinical trials will have to make more detailed data available...
Read moreNovel ‘Pay If You Clear’ scheme introduced in England for new hepatitis C treatment OLYSIO®
A new hepatitis C medicine, called simeprevir, is now available that the NHS in England will only...
Read moreGilead to appeal India patent ruling on hepatitis C drug
U.S.-based Gilead Sciences Inc will appeal the Indian patent office's rejection of its application...
Read moreWhy Now Is The Perfect Time To Buy GlaxoSmithKline plc
Life as a shareholder of GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US) has not been particularly...
Read moreCipla-Novartis patent row: DIPP looking into merit of case
Under Section 66 of IPA, Centre can revoke a patent in 'public interest' if it is of the opinion...
Read moreDr Reddy's Laboratories may file new drug applications with FDA within year
HYDERABAD: Drug maker Dr Reddy's Laboratories has said it may file two new drug applications (NDA)...
Read more